Back to Journals » Hepatic Medicine: Evidence and Research » Volume 2

Optimal management of hepatorenal syndrome in patients with cirrhosis

Authors Angeli P

Published 21 June 2010 Volume 2010:2 Pages 87—98

DOI https://doi.org/10.2147/HMER.S6918

Review by Single-blind

Peer reviewer comments 5


Paolo Angeli, Filippo Morando

Department of Clinical and Experimental Medicine, University of Padova, Italy

Abstract: Hepatorenal syndrome (HRS) is a functional renal failure that often occurs in patients with cirrhosis and ascites. HRS develops as a consequence of a severe reduction of effective circulating volume due to both an extreme splanchnic arterial vasodilatation and a reduction of cardiac output. There are 2 different types of HRS. Type 1 HRS, which is often precipitated by a bacterial infection, especially spontaneous bacterial peritonitis, is characterized by a rapidly progressive impairment of renal function. Despite its functional origin, the prognosis of type 1 HRS is very poor. Type 2 HRS is characterized by a stable or slowly progressive renal failure so that its main clinical consequence is not acute renal failure but refractory ascites and its impact on prognosis is less negative. New treatments (vasoconstrictors plus albumin, transjugular portosystemic shunt, and molecular adsorbent recirculating system), which were introduced in the past 10 years, are effective in improving renal function in patients with HRS. Among these treatments vasoconstrictors plus albumin can also improve survival in patients with type 1 HRS. Thus, this therapeutic approach has changed the management of this severe complication in patients with advanced cirrhosis.

Keywords: cirrhosis, ascites, bacterial infections, spontaneous bacterial peritonitis, renal failure, acute renal injury, chronic kidney disease, vasoconstrictors, terlipressin, midodrine, albumin, transjugular portosystemic shunt, renal replacement therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]